Monoclonal gammopathy of undetermined significance secondary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Shyam Patel [2]; Associate Editor(s)-in-Chief: Omer Kamal, M.D.[3]

Overview

Secondary prevention includes measures to delay the progression of MGUS to active multiple myeloma.

Secondary Prevention

Secondary prevention includes measures to delay the progression of MGUS to active multiple myeloma. Laboratory tests and physical examination are routinely performed. Laboratory testing includes^[1]:

References

↑ Tate JR, Graziani MS, Mollee P, Merlini G (2016). “Protein electrophoresis and serum free light chains in the diagnosis and monitoring of plasma cell disorders: laboratory testing and current controversies”. Clin Chem Lab Med. 54 (6): 899–905. doi:10.1515/cclm-2016-0268. PMID 27107838.

Template:WH Template:WS

[pmid27107838-1] Tate JR, Graziani MS, Mollee P, Merlini G (2016). “Protein electrophoresis and serum free light chains in the diagnosis and monitoring of plasma cell disorders: laboratory testing and current controversies”. Clin Chem Lab Med. 54 (6): 899–905. doi:10.1515/cclm-2016-0268. PMID 27107838.

[1]

Monoclonal gammopathy of undetermined significance secondary prevention

Overview

Secondary Prevention

References

Looking for the patient version?